(VIANEWS) – SEADRILL (SDRL.OL), SALMAR (SALM.OL), KBC (KBC.BR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SEADRILL (SDRL.OL)
67.8% sales growth and 4.22% return on equity
Seadrill Limited provides offshore contract drilling services to the oil and gas industry worldwide. It operates in three segments: Harsh Environment, Floaters, and Jack-ups Rigs. The company owns and operates drill ships, semi-submersible rigs, and jack-up rigs for operations in shallow and ultra-deep-water in benign and harsh environments. It serves oil super-majors, state-owned national oil companies, and independent oil and gas companies. Seadrill Limited was formerly known as Seadrill 2021 Limited. The company was incorporated in 2005 and is headquartered in Hamilton, Bermuda.
Earnings Per Share
As for profitability, SEADRILL has a trailing twelve months EPS of kr655.73.
PE Ratio
SEADRILL has a trailing twelve months price to earnings ratio of 0.8. Meaning, the purchaser of the share is investing kr0.8 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.22%.
More news about SEADRILL.
2. SALMAR (SALM.OL)
41.5% sales growth and 6.75% return on equity
SalMar ASA, an aquaculture company, produces and sells farmed salmon in Asia, North America, Europe, and internationally. The company operates through Fish Farming, Sales & Industry, Icelandic Salmon, and SalMar Aker Ocean segments. It is involved in the broodstock, lumpfish, and smolt production activities; and marine-phase farming, harvesting, processing, and selling farmed salmon. SalMar ASA was founded in 1991 and is headquartered in Kverva, Norway.
Earnings Per Share
As for profitability, SALMAR has a trailing twelve months EPS of kr6.67.
PE Ratio
SALMAR has a trailing twelve months price to earnings ratio of 77.51. Meaning, the purchaser of the share is investing kr77.51 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.75%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 9, 2023, the estimated forward annual dividend rate is 20 and the estimated forward annual dividend yield is 4%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 33.7% and positive 5.3% for the next.
Yearly Top and Bottom Value
SALMAR’s stock is valued at kr517.00 at 17:20 EST, way below its 52-week high of kr665.00 and way higher than its 52-week low of kr305.00.
More news about SALMAR.
3. KBC (KBC.BR)
31.5% sales growth and 15.09% return on equity
KBC Group NV, together with its subsidiaries, provides integrated bank-insurance services primarily for retail, private banking, small and medium sized enterprises, and mid-cap clients. The company offers demand deposits and savings accounts; home and mortgage loans; consumer finance and SME funding services; credit, investment fund and asset management, and life and non-life insurance; and cash management, payments, trade finance, lease, money market, capital market products, and stockbroking services. It also provides digital and mobile banking services. The company was formerly known as KBC Bank and Insurance Holding Company NV and changed its name to KBC Group NV in March 2005. KBC Group NV was incorporated in 1935 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, KBC has a trailing twelve months EPS of €7.68.
PE Ratio
KBC has a trailing twelve months price to earnings ratio of 7.91. Meaning, the purchaser of the share is investing €7.91 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.09%.
Yearly Top and Bottom Value
KBC’s stock is valued at €60.78 at 17:20 EST, way under its 52-week high of €72.46 and way above its 52-week low of €45.53.
More news about KBC.
4. MEDISTIM (MEDI.OL)
16.7% sales growth and 31.89% return on equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.33.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 36.02. Meaning, the purchaser of the share is investing kr36.02 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.89%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 25, 2023, the estimated forward annual dividend rate is 4.5 and the estimated forward annual dividend yield is 1.87%.
More news about MEDISTIM.
5. IMCD (IMCD.AS)
6.5% sales growth and 19.97% return on equity
IMCD N.V. distributes, markets, and sells specialty chemicals and ingredients in the Netherlands, rest of Europe, the Middle East, Africa, North America, South America, and the Asia-Pacific. The company offers bioactives, biocides, chelates, functional additives, rheology modifiers, silicones, solubilisers, and solvents; active pharmaceutical, agrochemicals, biopharma, excipients and formulation, nutraceuticals, and regulated synthesis; actives, UV sunscreens, rheology modifiers, thickeners, surfactants, emulsifiers, emollients, elastomers, humectants, waxes, film formers, functional powders, hair styling polymers, hair conditioners, solvents, solubilizers, pigments, pearls, colorants, opacifiers, pearlisers, preservatives, antioxidants, additives, fragrances, and essential oils; and resins and binders, additives, functional fillers, and specialty solvents. It also provides taste, texture, nutrition, and function; base oil, fuel addictive, lubricants addictive, lubricants finished fluids, solvents, degreasers and fuel, compounds, and upstream, midstream and downstream oil, gas and energy; bio-based chemicals, binders, corrosion inhibitors, catalysts, intermediates, monomers, organic building blocks, processing aids, reactive diluents, solvents, and surfactants. IMCD N.V. was founded in 1995 and is headquartered in Rotterdam, the Netherlands.
Earnings Per Share
As for profitability, IMCD has a trailing twelve months EPS of €5.06.
PE Ratio
IMCD has a trailing twelve months price to earnings ratio of 25.08. Meaning, the purchaser of the share is investing €25.08 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.97%.
Sales Growth
IMCD’s sales growth is 21.3% for the present quarter and 6.5% for the next.
More news about IMCD.
